Discovery may aid remission of ulcerative colitis

McMaster University researchers have identified a specific chemical that may trigger remission in patients with the debilitating disease of ulcerative colitis.

The team from the Farncombe Family Digestive Health Research Institute has found that people in long-term remission of have elevated levels of the same chemical, prostaglandin D2, which they previously found to be important in promoting healing and maintaining remission of the condition in laboratory rats.

"The levels of prostaglandin D2 were only elevated in those patients in long-term remission, and that suggests it is a key factor in preventing new episodes of ulcerative colitis," said John Wallace, director of the Institute and a professor of medicine for the Michael G. DeGroote School of Medicine.

Ulcerative colitis impacts 100,000 Canadians and millions worldwide, but has an unknown cause and limited treatment options. Most people are never cured, and often require surgical removal of the colon.

The discovery may lead to a new treatment for which would promote production of D2, Wallace said. "It is entirely possible our findings could extend to Crohn's disease as well."

The study by Wallace and post doctoral student Linda Vong with colleagues from the University of Calgary is being published in the prestigious journal (PNAS) on June 14.

Citation: Discovery may aid remission of ulcerative colitis (2010, June 14) retrieved 20 May 2019 from https://medicalxpress.com/news/2010-06-discovery-aid-remission-ulcerative-colitis.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more